ライフサイエンスコーパス: gastrointestinal symptom

1 (10% of the overall group) due to persistent gastrointestinal symptoms.

2 adverse events were headache, asthenia, and gastrointestinal symptoms.

3 291746) had frequent (>/= 3 days/week) upper gastrointestinal symptoms.

4 f D. fragilis positive children with chronic gastrointestinal symptoms.

5 ffects in the antibiotic group, particularly gastrointestinal symptoms.

6 ned by a combination of chronic or recurrent gastrointestinal symptoms.

7 ow in FODMAPs effectively reduced functional gastrointestinal symptoms.

8 entations were fever, weakness, myalgia, and gastrointestinal symptoms.

9 considered in pediatric patients with upper gastrointestinal symptoms.

10 lated adverse events were largely limited to gastrointestinal symptoms.

11 , flushing, tachycardia and headache but not gastrointestinal symptoms.

12 with non-IgE-mediated cow's milk allergy and gastrointestinal symptoms.

13 The acute phase is characterized by gastrointestinal symptoms.

14 ated with marked peripheral eosinophilia and gastrointestinal symptoms.

15 verse event, followed by fatigue, edema, and gastrointestinal symptoms.

16 eadache, confusion, and neuropsychiatric and gastrointestinal symptoms.

17 nced systemic reactions, and 49% experienced gastrointestinal symptoms.

18 dications commonly caused withdrawals due to gastrointestinal symptoms.

19 gnostic possibility for patients with common gastrointestinal symptoms.

20 e varied, half of the patients initially had gastrointestinal symptoms.

21 yed gastric emptying by scintigraphy without gastrointestinal symptoms.

22 time, and the severity of psychological and gastrointestinal symptoms.

23 T regulatory CD4+ cells, and amelioration of gastrointestinal symptoms.

24 atory bowel disorder that is associated with gastrointestinal symptoms.

25 malabsorption is associated with unexplained gastrointestinal symptoms.

26 een-found patients tend to have little or no gastrointestinal symptoms.

27 ars or diagnosed with CMA with predominantly gastrointestinal symptoms.

28 ollow-up, in pediatric patients with chronic gastrointestinal symptoms.

29 e been reported in children with and without gastrointestinal symptoms.

30 : 9.4% [95% CI 6.6-12.2]), partly because of gastrointestinal symptoms.

31 Celiac disease causes a wide range of gastrointestinal symptoms.

32 ts discontinued the study, mostly because of gastrointestinal symptoms.

33 a breath test and could not be predicted by gastrointestinal symptoms.

34 specimens at least monthly and when ill with gastrointestinal symptoms.

35 s measured and seems to have aggravated some gastrointestinal symptoms.

36 noncases were less likely than cases to have gastrointestinal symptoms.

37 16 patients had no gastrointestinal symptoms.

38 re dose-related and involved transient upper gastrointestinal symptoms.

39 es were used to measure hunger, satiety, and gastrointestinal symptoms.

40 y scores had a positive correlation with all gastrointestinal symptoms.

41 spital because of dehydration and persistent gastrointestinal symptoms.

42 ing to absence of gut innervation and severe gastrointestinal symptoms.

43 uch as ataxia or neuropathy, with or without gastrointestinal symptoms.

44 , even in mild disease and in the absence of gastrointestinal symptoms.

45 ode of PPOI characterized by upper and lower gastrointestinal symptoms.

46 infusions of the tastants did not result in gastrointestinal symptoms.

47 ortant role in assessing patients with upper gastrointestinal symptoms.

48 treatment resistant, upper or lower chronic gastrointestinal symptoms.

49 ty-three percent of patients with MEN 2B had gastrointestinal symptoms 1 to 24 years before the diagn

50 pliance with therapy (19.7, 1.66-234.4), and gastrointestinal symptoms (11.5, 1.23-107.0) were indepe

51 polyps or cancer (30.1%), bleeding (31.2%), gastrointestinal symptoms (11.8%), or a positive result

52 the meat after returning home and developed gastrointestinal symptoms 2 days later.

53 s for discontinuation were inefficacy (30%), gastrointestinal symptoms (29%), medication noncomplianc

54 ad eschar, 29% had lymphadenopathy, 100% had gastrointestinal symptoms, 34% had neurologic symptoms,

55 Of the 20, 5 had arthropathy, 5 had gastrointestinal symptoms, 4 had a rising serum ferritin

56 Five of 12 had gastrointestinal symptoms (42%).

57 77), and 4.9% in the remaining patients with gastrointestinal symptoms (55/1122).

58 a sure diagnosis of non-IgE-mediated CMA and gastrointestinal symptoms (97 boys, 56.4%; age, 6.37 m;

59 analogue scales assessing the severity of 5 gastrointestinal symptoms (abdominal pain, bloating, nau

60 We defined CFP case-patients as persons with gastrointestinal symptoms (abdominal pain, vomiting, dia

61 intolerance is overreported in subjects with gastrointestinal symptoms after lactose ingestion.

62 Chronic gastrointestinal symptoms after pelvic radiotherapy are

63 Gastrointestinal symptoms after pelvic radiotherapy, whi

64 f applied appropriately to patients with new gastrointestinal symptoms after radiotherapy, can identi

65 V-HD had gastroenteritis, and 1 had multiple gastrointestinal symptoms; all recovered.

66 estinal symptoms, followed by respiratory or gastrointestinal symptoms alone; the best outcomes were

67 Leukopenia, thrombocytopenia, gastrointestinal symptoms, alopecia, and fatigue were th

68 s, neutralizing anti-IL-17 or -IL-22 Abs, or gastrointestinal symptoms, although scarcity of the avai

69 8/9 had non specific upper gastrointestinal symptoms and 3/9 had rectocolic inflamm

70 cline delay and fatal outcome, such as early gastrointestinal symptoms and a history of alcoholism or

71 e describe a kindred with slowly progressive gastrointestinal symptoms and autonomic neuropathy cause

72 Norovirus shedding was associated with gastrointestinal symptoms and concomitant viremia in 54.

73 An association between gastrointestinal symptoms and contact with floodwater wa

74 Various gastrointestinal symptoms and diagnoses were strong pred

75 neuromodulators in the treatment of chronic gastrointestinal symptoms and FGIDs.

76 gnificantly decreased vomiting frequency and gastrointestinal symptoms and improved quality of life i

77 tool colonization in 29% of patients without gastrointestinal symptoms and in 55% of patients with pr

78 re acceptable than AA-MFs and noted improved gastrointestinal symptoms and less hunger with GMP-MFs.

79 e the long-term outcome of gastric emptying, gastrointestinal symptoms and nutritional status after l

80 The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were meas

81 in the presence of gastrointestinal and non-gastrointestinal symptoms and overlap syndromes.

82 agents were commonly associated with adverse gastrointestinal symptoms and poor palatability.

83 Patients with APECED frequently have gastrointestinal symptoms and seroreactivity against sec

84 ore, physicians should monitor ASA users for gastrointestinal symptoms and signs of ulcer, particular

85 Finally, the prevalence of upper gastrointestinal symptoms and the frequency of establish

86 Validated questionnaires were used to assess gastrointestinal symptoms and the modified body mass ind

87 n healthy volunteers on hunger, satiety, and gastrointestinal symptoms and the release of GLP-1 and P

88 Gastrointestinal symptoms and their impact on daily acti

89 tionnaires to describe the onset and type of gastrointestinal symptoms and treatment they had before

90 The high frequency of gastrointestinal symptoms and weight loss mirrors result

91 GE was remarkably common and associated with gastrointestinal symptoms and with measures of early and

92 flushing, tachycardia, and headache, but not gastrointestinal symptoms), and reduction in itching and

93 Three patients (21%) experienced gastrointestinal symptoms, and 1 (7%) discontinued the u

94 children had respiratory complaints, 30% had gastrointestinal symptoms, and 63% of children with thes

95 related to syncope, respiratory symptoms, or gastrointestinal symptoms, and a physician was frequentl

96 ients with the disease might have mainly non-gastrointestinal symptoms, and as a result patients pres

97 observed toxicity included myelosuppression, gastrointestinal symptoms, and asymptomatic hyperbilirub

98 umami) on food intake, hunger and fullness, gastrointestinal symptoms, and gastrointestinal peptide

99 ctors, nutritional outcomes, adverse events, gastrointestinal symptoms, and health-related quality of

100 reases in odds of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.

101 increased risk of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.

102 e and included respiratory tract infections, gastrointestinal symptoms, and hypertension.

103 vents with fedratinib treatment were anemia, gastrointestinal symptoms, and increased levels of liver

104 MPS withheld/discontinued due to leukopenia, gastrointestinal symptoms, and infection were 12 of 100,

105 depleted plasma concentrations of serotonin, gastrointestinal symptoms, and motor-sensory function in

106 h), abnormal pupillary light response, upper gastrointestinal symptoms, and neurogenic bladder.

107 status, use of opioids, blood transfusions, gastrointestinal symptoms, and sleep disturbance items,

108 t (29%) had lymphadenopathy, eight (29%) had gastrointestinal symptoms, and three (11%) had stiff nec

109 Although gastrointestinal symptoms are common after the acute pha

110 Gastrointestinal symptoms are common in children with au

111 s well described in long-term follow-up, and gastrointestinal symptoms are common, data on gut and pa

112 New gastrointestinal symptoms are frequent after pelvic radi

113 to base a confident conclusion as to whether gastrointestinal symptoms are more common in children wi

114 variable combination of chronic or recurrent gastrointestinal symptoms are present in the absence of

115 Nausea and gastrointestinal symptoms are the chief tolerability iss

116 vidence that, in a major subset of patients, gastrointestinal symptoms arise first and only later do

117 tives included patients' assessment of their gastrointestinal symptoms as well as treatment safety an

118 ta from 1848 consecutive adult patients with gastrointestinal symptoms at 2 hospitals in Hamilton, On

119 Children presenting with gastrointestinal symptoms at the Royal Hospital for Sick

120 ending on different assumptions, the cost of gastrointestinal symptoms attributable to water recreati

121 ic survey asked detailed questions regarding gastrointestinal symptoms before and after the instituti

122 Tap water consumption was not related to gastrointestinal symptoms before, during, or after the f

123 The drug was well tolerated, with gastrointestinal symptoms being the most common complain

124 ples collected from neonates with or without gastrointestinal symptoms between 1999 and 2000 were gen

125 ed mycophenolate sodium (EC-MPS) in terms of gastrointestinal symptom burden has been evaluated previ

126 Change in gastrointestinal symptom burden was evaluated using a va

127 itis) and typically developing children with gastrointestinal symptoms but no evidence of gastrointes

128 Patients with MEN 2B have significant gastrointestinal symptoms, but less than a third had sur

129 f children with non-IgE-mediated CMA-related gastrointestinal symptoms by contributing in determining

130 SFTS disease is characterized by gastrointestinal symptoms, chills, joint pain, myalgia,

131 shing and pruritus, dysautonomia, functional gastrointestinal symptoms, chronic pain, and connective

132 The questionnaire included gastrointestinal symptoms commonly reported to be associ

133 ee diet associated with small improvement in gastrointestinal symptoms compared with no gluten-free d

134 A total of 2334 patients with gastrointestinal symptoms composed the study group, whic

135 th few side effects, including headaches and gastrointestinal symptoms, concerns are raised regarding

136 In all participants, gastrointestinal symptoms consistently and significantly

137 Reported worldwide as causing human gastrointestinal symptoms, D. fragilis is very common an

138 r and neutropenia (28%), infection (9%), and gastrointestinal symptoms, dehydration, and vincristine

139 Reported gastrointestinal symptoms did not differ significantly b

140 d age, gender, body mass index, and baseline gastrointestinal symptoms did not predict whether celiac

141 CVID patients with gastrointestinal symptoms differed from asymptomatic CVI

142 vagal afferent input to the NTS secondary to gastrointestinal symptoms during CTA expression (e.g. di

143 be considered in future cases of persistent gastrointestinal symptoms during food allergy immunother

144 An increase in the incidence of gastrointestinal symptoms during the flood was observed

145 medical conditions that themselves result in gastrointestinal symptoms (e.g., inflammatory bowel dise

146 he subset of PPOI patients who display lower gastrointestinal symptoms exclusively after surgery.

147 The surveys measured gastrointestinal symptoms experienced during the past ye

148 nts presenting with combined respiratory and gastrointestinal symptoms, followed by respiratory or ga

149 Over two-thirds of patients with upper gastrointestinal symptoms following RYGB will have one o

150 study of patients (>/=18 years) with chronic gastrointestinal symptoms for 12 months or more after ra

151 logical, and genetic factors associated with gastrointestinal symptoms for patients with mastocytosis

152 ecal specimens from 62 Kuwaiti children with gastrointestinal symptoms found to be positive by micros

153 glia could, to a certain extent, explain the gastrointestinal symptoms frequently experienced by CF p

154 cases were reported in persons who developed gastrointestinal symptoms from April through 15 June, fo

155 effect of sex on gastric emptying, appetite, gastrointestinal symptoms, glucose, or gut hormones (P >

156 Since November 2000, coincidentally, data on gastrointestinal symptoms had been collected for a drink

157 nty-one percent of patients with MEN-2B with gastrointestinal symptoms had radiographic imaging, 32%

158 nificant proportion of children with ASD and gastrointestinal symptoms have histologic evidence of il

159 factors, pulmonary function, vitamin status, gastrointestinal symptoms, health-related quality of lif

160 d improvement in neuropathic pain, sweating, gastrointestinal symptoms, hearing loss, and pulmonary s

161 Correlations were found among gastrointestinal symptoms, histopathologic findings, cyt

162 tion of participants who reported individual gastrointestinal symptoms; however, more controls report

163 thy individuals and frequently manifest with gastrointestinal symptoms; however, their ability to cau

164 ociated antibodies decreased (P < .003), and gastrointestinal symptoms improved to a greater extent t

165 (87%), shortness of breath in 11 (48%), and gastrointestinal symptoms in 8 (35%); 20 patients (87%)

166 examined the effect of a gluten-free diet on gastrointestinal symptoms in a cohort of US patients wit

167 e the first report of an increase in endemic gastrointestinal symptoms in a longitudinal cohort prosp

168 e United States described high prevalence of gastrointestinal symptoms in children with autistic diso

169 c inflammatory bowel disease associated with gastrointestinal symptoms in CVID is a unique combinatio

170 ties are associated with increased levels of gastrointestinal symptoms in general.

171 (FODMAPs) often is used to manage functional gastrointestinal symptoms in patients with irritable bow

172 t in an increase in the endemic incidence of gastrointestinal symptoms in the United States.

173 % of the infections were in children who had gastrointestinal symptoms, including acute watery diarrh

174 Patients presented with gastrointestinal symptoms, including diarrhea, flatulenc

175 frequently associated with specific adverse gastrointestinal symptoms, including emesis, diarrhea, a

176 One patient developed predominantly gastrointestinal symptoms, including nausea, vomiting, a

177 that patients with radiation-induced chronic gastrointestinal symptoms, including those patients with

178 Lactose intolerance resulting in gastrointestinal symptoms is a common health concern.

179 renal failure, neurologic abnormalities, and gastrointestinal symptoms, is common.

180 ffected individuals suffered with prevailing gastrointestinal symptoms leading to the diagnosis of AL

181 In rare cases this can result in atypical gastrointestinal symptoms, making the diagnosis of Nutcr

182 mmunosuppressive regimen with posttransplant gastrointestinal symptoms may benefit from a conversion

183 Primary outcome was change in level of gastrointestinal symptoms, measured on a visual-analog-s

184 Adverse events included gastrointestinal symptoms (n = 9), mild stomatitis (n =

185 maturely discontinued treatment due to ECMPS gastrointestinal symptoms (n=2), skin intolerance to APM

186 Most common adverse events included mild gastrointestinal symptoms (nausea [47%], diarrhea [36%],

187 one patients were asymptomatic, 24 had minor gastrointestinal symptoms not requiring medical therapy,

188 However, the frequency of gastrointestinal symptoms observed in population-based s

189 Minimal gastrointestinal symptoms occurred during the trial.

190 The following gastrointestinal symptoms occurred more frequently and w

191 Gastrointestinal symptoms occurred more often with whey

192 rotoxin (CPE) is responsible for causing the gastrointestinal symptoms of C. perfringens type A food

193 Medical history and gastrointestinal symptoms of patients with mastocytosis

194 are not involved in the pathogenesis or the gastrointestinal symptoms of PD.

195 ium perfringens enterotoxin (CPE) causes the gastrointestinal symptoms of the second most common bact

196 ms began a median of 10.5 days after initial gastrointestinal symptoms, often accompanied by fever (n

197 Patients without any gastrointestinal symptoms or disease (n = 192) composed

198 evidence of gluten sensitivity without overt gastrointestinal symptoms or evidence of small-bowel inf

199 iduals for at least 6 months without causing gastrointestinal symptoms or impacting the composition o

200 6 tuberculosis patients with AIDS and either gastrointestinal symptoms or non-compliance developed ac

201 was 15% or less, and the tests used included gastrointestinal symptoms or serum antibody tests.

202 e); 2) non-classical (extraintestinal and/or gastrointestinal symptoms other than diarrhea); 3) subcl

203 .05) but also resulted in an increase in the gastrointestinal symptoms pain (P-treatment x time inter

204 nts presenting with neurologic, cardiac, and gastrointestinal symptoms, particularly in the presence

205 ) from clinics in London, UK, with new-onset gastrointestinal symptoms persisting 6 months after pelv

206 en's race/ethnicity but not their associated gastrointestinal symptoms predicted whether celiac testi

207 Assessment of gastrointestinal symptoms, psychological traits, and dai

208 Events for which the gastrointestinal symptom questionnaire was most discrimi

209 the validated Reflux Symptom Score (RSS) and Gastrointestinal Symptom Rating Scale (GSRS) questionnai

210 The Gastrointestinal Symptom Rating Scale (GSRS) was complet

211 weeks postbaseline), patients completed the Gastrointestinal Symptom Rating Scale (GSRS), Gastrointe

212 mptom burden was evaluated using a validated Gastrointestinal Symptom Rating Scale (GSRS).

213 ionwide study, 596 patients filled validated Gastrointestinal Symptom Rating Scale and Psychological

214 Therefore, this study aimed to translate the Gastrointestinal Symptom Rating Scale for Irritable Bowe

215 had a significantly greater decrease in the Gastrointestinal Symptom Rating Scale indigestion syndro

216 Symptoms were measured by Gastrointestinal Symptom Rating Scale Irritable Bowel Sy

217 The indigestion subscore of the Gastrointestinal Symptom Rating Scale questionnaire (GSR

218 A modified Gastrointestinal Symptom Rating Scale questionnaire was

219 The Gastrointestinal Symptom Rating Scale Reflux dimension w

220 outcome was a change from baseline in total Gastrointestinal Symptom Rating Scale score of a minimal

221 rence in average on-treatment Celiac Disease Gastrointestinal Symptom Rating Scale score.

222 symptoms, as expressed by the change in the Gastrointestinal Symptom Rating Scale scores (1.7+/-0.3

223 After comparing changes in Gastrointestinal Symptom Rating Scale total scores and s

224 symptoms were assessed (using the validated gastrointestinal symptom rating scale) before and after

225 parameters, and tolerability as rated by the Gastrointestinal Symptom Rating Scale.

226 Faecal calprotectin (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel S

227 , MMF-treated renal transplant patients with gastrointestinal symptoms receiving cyclosporine or tacr

228 irus infection, with relatively high rate of gastrointestinal symptoms reported.

229 ubset of patients have developed significant gastrointestinal symptoms requiring discontinuation of t

230 ymptoms not requiring medical therapy, 3 had gastrointestinal symptoms requiring medical therapy, and

231 The Gastrointestinal Symptom Response Scale was completed we

232 s the change in symptoms using the validated Gastrointestinal Symptom Score (GIS(c)).

233 thy (P = .05), and a greater composite upper gastrointestinal symptom score (P < .05).

234 Subjects with IBS had lower overall gastrointestinal symptom scores (22.8; 95% confidence in

235 vine immunoglobulin/protein isolate (SBI) on gastrointestinal symptom scores and quality of life (QoL

236 Gastrointestinal symptom scores for diarrhea (P = 0.0298

237 on for hereditary ATTR amyloidosis, although gastrointestinal symptom scores had increased over time.

238 ip between these variables and the course of gastrointestinal symptom scores over time was analyzed u

239 Gastrointestinal symptom scores were computed using Euro

240 Gastrointestinal symptom scores, however, had increased

241 depth, serology and laboratory test results, gastrointestinal symptom scores, physiologic well-being,

242 baseline to 12-month follow-up decreases in gastrointestinal symptom severity (estimated mean differ

243 h placebo, relamorelin did not improve other gastrointestinal symptoms, such as abdominal pain and sa

244 also associated with increased prevalence of gastrointestinal symptoms, suggesting that the Na(+) cha

245 Children with gastrointestinal symptoms suggestive of GER who do not r

246 better improvements in radiotherapy-induced gastrointestinal symptoms than did patients given usual

247 The gastrointestinal symptoms that followed the first intrad

248 Other than pain, the most common reported gastrointestinal symptom was nausea (86 %).

249 At least one gastrointestinal symptom was reported by 619 of 1620 (38

250 increased susceptibility to colon cancer and gastrointestinal symptoms, we aimed to identify rhythmic

251 l, children aged 3-12 years with >4 weeks of gastrointestinal symptoms were allocated using block ran

252 e years after liver transplantation, whereas gastrointestinal symptoms were assessed in median nine m

253 Injection site reactions and gastrointestinal symptoms were common adverse events in

254 hemoglobin (HbA1c), complications of DM, and gastrointestinal symptoms were evaluated.

255 on, blood glucose, appetite perceptions, and gastrointestinal symptoms were measured during 90-min in

256 showed variable uptake in the normal bowel, gastrointestinal symptoms were mild or absent, and in no

257 Gastrointestinal symptoms were present in only 13%.

258 Patients with chronic upper gastrointestinal symptoms were prospectively evaluated.

259 Gastrointestinal symptoms were seen in some animals.

260 physical functioning, and more vasomotor and gastrointestinal symptoms were significant risk factors

261 Among tolerability measures, gastrointestinal symptoms were significantly greater in

262 Gastrointestinal symptoms were significantly more preval

263 Gastrointestinal symptoms were somewhat more common and

264 Gastrointestinal symptoms were the most common adverse e

265 Some gastrointestinal symptoms were worse in patients treated

266 Gastrointestinal symptoms were, collectively, most commo

267 Medical symptoms, particularly gastrointestinal symptoms, were common.

268 The patient had worsened gastrointestinal symptoms with mycophenolate mofetil or

269 sons who ate at a suspect facility developed gastrointestinal symptoms within 24 h, including 18 who